Chiauranib clinical trials
Also written CS2164.
How each study uses chiauranib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the chiauranib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
15 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test chiauranib.
- Feb 2027Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaPhase 2 · Chipscreen Biosciences, Ltd.
Studies
Open first, then newest update. How each study uses chiauranib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 3Chipscreen Biosciences, Ltd.NCT07445295Written as Chiauranib
- Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerRecruitingPhase 3Chipscreen Biosciences, Ltd.NCT04921527Written as chiauranib
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.RecruitingPhase 1/2Chipscreen Biosciences, Ltd.NCT05271292Written as Chiauranib
- Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 2Chipscreen Biosciences, Ltd.NCT06492915Written as Chiauranib
- Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)CompletedPhase 2Chipscreen Biosciences, Ltd.NCT05497843Written as Chiauranib
- A Phase II Study of Chiauranib in Combine With Capecitabine in TNBCTerminatedPhase 2Chipscreen Biosciences, Ltd.NCT05336721Written as Chiauranib
- Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerCompletedPhase 3Chipscreen Biosciences, Ltd.NCT04830813Written as Chiauranib
- Mass Balance Study of [14C]ChiauranibCompletedNot applicableChipscreen Biosciences, Ltd.NCT05371899Written as Chiauranib
- Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung CancerCompletedPhase 1Chipscreen Biosciences, Ltd.NCT03216343Written as Chiauranib
- Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy VolunteersCompletedPhase 1Chipscreen Biosciences, Ltd.NCT05346601Written as Chiauranib
- Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's LymphomaCompletedPhase 1/2Chipscreen Biosciences, Ltd.NCT03974243Written as Chiauranib
- Study of Chiauranib in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 1/2Chipscreen Biosciences, Ltd.NCT03245190Written as Chiauranib
- Phase Ib Study of Chiauranib in Patients With Ovarian CancerCompletedPhase 1/2Chipscreen Biosciences, Ltd.NCT03166891Written as Chiauranib
- Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's LymphomaTerminatedPhase 1Chipscreen Biosciences, Ltd.NCT03074825Written as Chiauranib
- Phase I Study of Chiauranib in Patients With Advanced Solid TumorsCompletedPhase 1Chipscreen Biosciences, Ltd.NCT02122809Written as Chiauranib
Given beside what is tested · 1 — chiauranib is usual care or a partner of the new treatment
Codes
What other systems call chiauranib · ClinicalTrials.gg INT001282
- MeSH (NLM) C000705608chiauranibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F40IRN5981IBCASERTIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705608 | chiauranib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F40IRN5981 | IBCASERTIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.